Drug Database
CH

chlorhexidine dihydrochloride + dexamethasone + nystatin (Nystalocal)

✓ Approved

Medinova · 小分子 · 小分子

什么是 chlorhexidine dihydrochloride + dexamethasone + nystatin?

chlorhexidine dihydrochloride + dexamethasone + nystatin 是一种小分子,由Medinova研发。该药已获批,用于治疗相关适应症,给药途径:Topical。

药物档案

商品名Nystalocal
公司Medinova
药物类别小分子
给药途径Topical
状态Approved

治疗适应症

chlorhexidine dihydrochloride + dexamethasone + nystatin 针对 2 个适应症,涉及 2 个治疗领域。

治疗领域疾病/病症分期
InvestigationsDermatologic examination✓ Approved
Infections and infestationsCandida infection✓ Approved

相关研究文献

PubMedItalian journal of pediatrics2026-11-19

Skin safety during umbilical venous catheter insertion using 2% chlorhexidine gluconate in 70% isopropyl alcohol: a prospective observational study.

D'Andrea Vito V, Prontera Giorgia G, Monachini Cecilia C, Cerreti Micaela M et al.

Umbilical venous catheter (UVC) placement in NICU requires effective antisepsis to minimize catheter-related bloodstream infections. Chlorhexidine gluconate (CHG) in isopropyl alcohol (IPA) is commonly used, but its safety in preterm infants is debated. This study evaluates the skin safety of 2% CHG in 70% IPA during UVC placement in neonates. A prospective analysis of neonates admitted to a tertiary NICU from January 2021 to December 2024 was conducted. Skin reactions were assessed at 30 min, 24 h, and 48 h post-procedure. The primary outcome was the incidence of skin lesions categorized according to a dermatitis severity score. Among 506 neonates, 48.4% had a gestational age ≤ 32 weeks. No severe lesions were observed. Erythema and discoloration were common but resolved within 48 h. The incidence of erythema decreased with increasing gestational age. Only two catheters were removed as a result of catheter-related bloodstream infections (0.89 per 1000 catheter days). 2% CHG in 70% IPA showed a favorable safety profile in neonates undergoing UVC placement when appropriate precautions were observed.

PMID 43053188
阅读全文 →
PubMedBMC oral health2026-11-19

Antibacterial efficacy of octenidine, sodium hypochlorite, and their combination against multispecies endodontic biofilms: an in vitro CLSM study.

Baştürk Özer Muazzez Naz MN, Çulha Emre E, Özer Hasan Yıldırım HY

The current study used confocal laser scanning microscopy (CLSM) to assess the antibacterial activity of octenidine hydrochloride (OCT) both by itself and in combination with sodium hypochlorite (NaOCl) on the eradication of biofilms. Forty dentin blocks were inoculated with a biofilm consisting of Enterococcus faecalis, Staphylococcus aureus, Pseudomonas aeruginosa, and Streptococcus mutans. After a 3-week incubation period, the resulting diverse biofilm was imaged using a scanning electron microscope (SEM). Five groups were formed: Saline solution (SS), 2% chlorhexidine (CHX), 5% NaOCl, undiluted OCT (containing 0.1% octenidine), and a 5% NaOCl / undiluted OCT mixture (90:10 ratio). Samples were subjected to the relevant agent for 5 min. The percentage of dead cell bacteria was evaluated using the Live/Dead BacLight Viability Kit dye under CLSM. Image analysis was performed with Image J software. The Kruskal-Wallis and Dunn's tests were used to statistically assess the data, with a significance threshold of p < 0.05. CLSM images showed that the NaOCl alone eliminated the amount of bacteria similar to NaOCl/OCT mixture group (p > 0.05) and significantly more bacteria compared to other solutions (p < 0.05). NaOCl/OCT mixture group was also similar to the OCT alone group (p > 0.05), while CHX and SS groups represented the least amount of dead bacteria than other groups (p < 0.05). Under the experimental conditions, the NaOCl/OCT combination demonstrated antibacterial activity comparable to NaOCl alone. While 5% NaOCl remained the most effective agent, the addition of OCT did not provide a statistically significant increase in antibacterial efficacy. SS and CHX exhibited significantly lower antibacterial effects.

PMID 43052949
阅读全文 →
PubMedPlant foods for human nutrition (Dordrecht, Netherlands)2026-11-19

Harnessing the Antibacterial Potential of Star Fruit Extract against MRSA: Metabolic Profiling, Molecular Docking, and In Vitro Wound-Healing Effects.

Eraqi Walaa A WA, Mohamed Sally A SA, Hanafi Maha M, Salem Mohamed A MA et al.

Averrhoa carambola L. (star fruit) is recognized for its nutritional value and bioactive constituents. This study investigated its antibacterial and antibiofilm activities against methicillin-resistant Staphylococcus aureus (MRSA) and its potential to promote wound healing. The in vitro antibacterial activity of the extract was evaluated against six MRSA strains by determining the minimum inhibitory concentration (MIC), minimum bactericidal concentration (MBC), and time-kill kinetics. The extract exhibited a uniform MIC of 1.95 mg/mL against all tested MRSA strains, while MBC values ranged from 15.6 to 125 mg/mL. Biofilm inhibition was assessed using a crystal violet assay, while transmission electron microscopy and intracellular ion leakage analysis were used to investigate the antibacterial mechanism. The extract significantly inhibited biofilm formation at 0.5 × and 0.25 × MIC, particularly against MS3 and MS15 strains (p ≤ 0.05). The extract induced membrane damage and significant leakage of intracellular phosphate (p = 0.0036) and potassium (p = 0.0001). Its cytocompatibility and wound-healing activity were evaluated using primary human adult dermal fibroblasts (HDFa) and an in vitro scratch assay. The extract showed an EC50 of 2.96 mg/mL without reducing HDFa viability and significantly enhanced wound closure to 70%, compared with 82% for dexamethasone. UPLC-QTOF-MS/MS profiling identified 130 metabolites, with flavonoids representing the predominant class (49 compounds). Molecular docking further predicted favorable binding interactions between selected flavonoids and collagenase, elastase, and lipase. These findings demonstrate the antibacterial, antibiofilm, and in vitro wound-healing potential of star fruit extract against MRSA.

PMID 43052601
阅读全文 →
PubMedEye (London, England)2026-11-19

Incidence and visual outcomes of post-intravitreal injection endophthalmitis: a single-centre analysis of 224,397 injections.

Kayikci Mahmutoglu Gulce G, Simsek Metehan M, Cevik Sadik Gorkem SG, Arici Murat M et al.

Post-injection endophthalmitis (PIE) is a rare, vision-threatening complication of intravitreal injections (IVIs). As IVI volumes rise globally, optimising prevention and management is crucial. This study evaluated PIE incidence, risk factors, microbiology, and outcomes over ten years. A retrospective cohort study of 224,397 IVIs. We analysed demographics, agent type, and preparation (pre-filled syringe [PFS] vs. manual aliquoting). Overall endophthalmitis incidence was 0.029% (n = 65), and 0.026% for anti-VEGFs. PFS-ranibizumab had the lowest incidence (0.014%) and was significantly safer than manually prepared bevacizumab (0.039%; OR: 2.74 [95% CI: 1.36-5.55], p = 0.003); vial-sourced aflibercept (0.027%) was intermediate and not statistically distinguishable from either. Culture positivity was 33.8% (n = 22), predominantly Gram-positive (81.8%), with Staphylococcus epidermidis being the most common (45.5%). In univariate analysis, culture positivity was the sole predictor of worse final visual acuity (VA) (p = 0.030), though limited by small sample sizes. Median VA worsened from 0.61 logMAR at baseline to 2.10 logMAR at presentation, recovering to 1.80 logMAR at final visit (p < 0.001). Among cases initially treated with tap and intravitreal antibiotics (TAI), 60% (21/35) required subsequent vitrectomy (PPV). No baseline clinical parameters predicted TAI success or PPV requirement (all p > 0.05). Dexamethasone implants, with their larger applicator, carried the highest risk. Among anti-VEGFs, PFS ranibizumab demonstrated the most favourable safety profile, with the lowest incidence of PIE. Manual immediate-use bevacizumab aliquoting is a safe, cost-effective alternative in resource-limited settings. In univariate analysis, culture positivity emerged as a negative prognostic factor, though this finding is limited by small sample sizes. Given unpredictable TAI responses, aggressive monitoring and a low PPV threshold are essential.

PMID 43052414
阅读全文 →
PubMedBMC pediatrics2026-11-18

Analysis of adverse reactions to low-dose dexamethasone in bronchopulmonary dysplasia of extremely premature infants: a retrospective study.

Zhuang Genmiao G, Xie Xiaohua X, Chen Jianan J

Bronchopulmonary dysplasia (BPD) represents a prevalent complication among extremely premature infants. Nonetheless, the optimal dosage, treatment duration, and safety profile of dexamethasone require further validation through clinical research. This study investigates the efficacy and safety of low-dose dexamethasone intervention for BPD in extremely preterm infants and establishes an evidence-based foundation for monitoring adverse drug reactions within this population. A retrospective analysis was conducted on 68 cases of extremely preterm infants between March 2016 and January 2024. Among them, 41 cases received dexamethasone treatment (dexamethasone group) while 27 cases did not (control group). The control group received standard respiratory support, nutritional support, anti-infection measures, and other conventional treatments, whereas the dexamethasone group received low-dose dexamethasone in addition to standard care. The primary outcome was a composite endpoint of severe BPD or in-hospital death. Multivariable binary logistic regression was performed adjusting for gestational age, birth weight, and respiratory severity score (RSS). The study compared the extubation success rate, severe BPD incidence, and adverse reactions between the two groups. After adjustment for gestational age, birth weight, and RSS, dexamethasone was associated with lower odds of the composite endpoint of severe BPD or death (adjusted OR = 0.26, 95%CI 0.09-0.55, P = 0.003) and severe BPD among survivors (adjusted OR = 0.27, 95%CI 0.10-0.59, P = 0.005), and higher odds of extubation success (adjusted OR = 2.88, 95%CI 1.20-7.57, P = 0.024). Hyperglycaemia occurred more frequently in the dexamethasone group (41.5% vs. 18.5%, adjusted OR = 2.04, 95%CI 0.82-4.97, P = 0.121), although the difference did not reach statistical significance. In this single-center retrospective cohort, low-dose dexamethasone was associated with lower odds of severe BPD or death and higher odds of extubation success after adjustment for gestational age, birth weight, and respiratory severity. Clinically relevant increases in adverse events, particularly hyperglycaemia, cannot be excluded given the limited sample size. Long-term growth was not assessed. These findings require validation in larger multicenter prospective studies.

PMID 43046014
阅读全文 →
PubMedBritish journal of pharmacology2026-11-18

Model-informed characterisation of the target therapeutic window for dexamethasone by quantitatively balancing foetal lung maturation and neurotoxicity in pregnant rats.

Song Ling L, Zhao Xiaoqi X, Du Ruihu R, Zhang Lei L et al.

Dexamethasone, a first-line treatment for neonatal respiratory distress syndrome (NRDS), promotes foetal lung maturation whilst simultaneously inducing neurotoxicity in offspring. We aimed to define the therapeutic window of dexamethasone for the treatment of NRDS. Pregnant rats were given dexamethasone at 0.1 or 0.4 mg·kg-1 to simulate clinically equivalent prenatal dexamethasone exposure. Half of the rats were anaesthetised, and surfactant proteins A and B in foetal lungs quantified. A pharmacokinetic/pharmacodynamics (PK/PD) model was developed to determine the minimum effective concentration. The remaining rats, delivered naturally, and their offspring underwent open-field testing. Messenger RNA sequencing of the foetal hippocampus was performed, and concentration-toxicity assays were conducted using H19-7/IGF-IR cells. Data were integrated with a maternal-foetal physiologically based pharmacokinetic (PBPK) model to determine the maximum tolerated concentration. A clinical PBPK for dexamethasone in pregnant women was used to simulate a potentially optimal dosing regimen. The PK/PD model adequately characterised dexamethasone-induced foetal lung maturation and indicated a minimal effective concentration of 1.63 ng·ml-1. The offspring of PDE rats exhibited significant behavioural changes. mRNA sequencing analysis suggested that neurotoxicity was mediated via the Wnt pathway and renin-angiotensin system, with BDNF and CMA1 identified as potential biomarkers of neurotoxicity. Cell-based assays suggested a neurotoxic threshold concentration of 17 ng·ml-1. For a therapeutic window of 1.63-17 ng·ml-1, PBPK model simulations indicated that a reduced dose regimen of 2.5 or 3 mg every 8 h for six doses may represent an optimised therapeutic strategy. This model-informed precision dosing strategy provides a rational approach to optimising clinical dexamethasone dosing regimens.

PMID 43046589
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多chlorhexidine dihydrochloride + dexamethasone + nystatin